1. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial
- Author
-
D. Tojjar, G. Bantwal, Y. Ono, T. Sasaki, Tomoyuki Nishida, Melanie J. Davies, J. L. Gross, and H. Seino
- Subjects
Insulin degludec ,Adult ,Blood Glucose ,Male ,medicine.medical_specialty ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,Urology ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Lower risk ,Drug Administration Schedule ,Time ,Insulin aspart ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Insulin Detemir ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Hypoglycemic Agents ,Meals ,Insulin Aspart ,Insulin detemir ,Glycated Hemoglobin ,Type 1 diabetes ,business.industry ,Fasting ,Middle Aged ,medicine.disease ,Confidence interval ,Hypoglycemia ,Insulin, Long-Acting ,Diabetes Mellitus, Type 1 ,Basal (medicine) ,Tolerability ,Female ,business ,medicine.drug - Abstract
The long-term safety and tolerability of insulin degludec (IDeg) was compared with that of insulin detemir (IDet), as basal treatment in participants with type 1 diabetes mellitus (T1DM). In the present multinational, 26-week core + 26-week extension, controlled, open-label, parallel-group trial, adults with T1DM were randomized to IDeg or IDet as basal insulin treatment combined with meal-time bolus insulin aspart. IDeg was administered once daily, whilst IDet was administered once or twice daily depending on patients' glycaemic control. After 1 year, IDeg provided a 33% lower rate of nocturnal hypoglycaemia compared with IDet: estimated rate ratio (IDeg : IDet) 0.67 [95% confidence interval (CI) 0.51; 0.88]; p
- Published
- 2015